Physician profile
Robert C Bowen
NPI 1225059611
$2,081.23
in general payments reported to CMS, 2019-2025
20 companies · $526 in 2025
The $526 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $22.83 · 2021: $34.95 · 2022: $351 · 2023: $461 · 2024: $513 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $393.03 | 2022-2025 | Arexvy, Shingrix |
| Abbvie INC. | $347.95 | 2022-2025 | Vraylar |
| Abbott Laboratories | $274.34 | 2022-2024 | Freestyle Libre 3, Proclaim |
| Novo Nordisk INC | $273.71 | 2023-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $255.03 | 2019-2025 | |
| Amgen INC. | $183.28 | 2019-2025 | Repatha, Otezla, Evenity |
| Gilead Sciences, INC. | $83.86 | 2019-2020 | |
| Masimo Corporation | $35.00 | 2019 | |
| Sunovion Pharmaceuticals INC. | $30.48 | 2022 | |
| Eisai INC. | $25.27 | 2025 | |
| Verity Pharmaceuticals INC. | $24.79 | 2024 | Tlando |
| Allergan, INC. | $20.22 | 2021 | |
| Boston Scientific Corporation | $19.53 | 2024 | |
| Phathom Pharmaceuticals, INC. | $18.48 | 2023 | Voquezna |
| Astellas Pharma US INC | $17.35 | 2024 | Veozah |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $17.17 | 2025 | Farxiga |
| Lilly USA, LLC | $16.59 | 2023 | Zepbound |
| Novartis Pharmaceuticals Corporation | $15.61 | 2019 | |
| Lundbeck LLC | $14.93 | 2025 | Rexulti |
| Amarin Pharma, INC. | $14.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bowen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.